[{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Launches Trial for ANJ900 to Treat T2D Patients with Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Anji Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anji Pharma Provides Update on ANJ900 Pivotal Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Trueline Therapeutics","sponsor":"Broad Institute of Harvard","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Anji Pharmaceutical
TTX-810 is an IND-enabling candidate, a MCL1 inhibitor, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.
Previous trials with ANJ900 demonstrated clinically meaningful glucose lowering with only one-third the plasma concentrations observed with currently marketed formulations of metformin.
ANJ900 (Metformin) is a gut-targeted formulation designed to lower glucose with reduced systemic exposure of metformin, so that patients who cannot take currently available formulations of metformin may achieve better glucose control.
ANJ908 (pradigastat) is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1), which plays a key role in the re-assembly of meal triglycerides and acts as a sensor of dietary fat intake.
Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor (ANJ810) program through a license from the Broad Institute of MIT and Harvard and will work to advance the program’s MCL1 inhibitors through clinical development.
Anji Pharma has initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease.